Chengdu Nuodikang Biopharmaceutical

Chengdu Nuodikang Biopharmaceutical is a specialized Chinese biotechnology company and a wholly-owned subsidiary of Tibet Rhodiola Pharmaceutical Holding Co. Based in Chengdu, Sichuan, the company serves as the primary research, development, and manufacturing hub for the group's biological drug portfolio. Its flagship product, Xinhuo (Recombinant Human Brain Natriuretic Peptide), is a Class 1 innovative biologic approved in China for the treatment of acute heart failure. Xinhuo acts as a potent vasodilator and diuretic, significantly improving cardiac function and patient outcomes in emergency settings. The company operates state-of-the-art GMP-certified facilities dedicated to recombinant DNA technology and protein purification. Chengdu Nuodikang is a critical player in China's cardiovascular therapeutic market, contributing the vast majority of its parent company's annual revenue through the commercial success of Xinhuo.